Quick answer
What do in vitro studies of sermorelin measure? They measure the response of pituitary somatotrophs or receptor-expressing cells to GHRH (1-29) peptides: GH release, cAMP accumulation and receptor-linked gene expression. In primary rat pituitary cells the median effective concentration is in the picomolar range and the effect starts within seconds; IGF-1 is not a pituitary-cell readout because it is produced downstream of GH in other tissues.
In vitro work with a GHRH peptide is some of the most reproducible work in the GH-axis literature, because the target cell, the receptor and the second messenger are all well defined. This article collects what published cell studies measured, translates their molar concentrations into the milligram-scale arithmetic of a lab vial, and notes where the field of view ends. It is intended for laboratory research use only; not for human consumption.
Which in vitro systems have been used with GHRH peptides
Sermorelin is GHRH (1-29) amide, so the in vitro literature that applies to it is the literature on GHRH and GHRH(1-29) peptides in pituitary and receptor-expressing cells. Five system types recur. The table lists them with what each reported, so that a reader can match a planned experiment to a precedent.
| System | What was measured | Reported result |
|---|---|---|
| Primary rat anterior pituitary cell culture | GH release after exposure to native or synthetic GRF | Identical dose-response curves for native and synthetic peptides; median effective concentration about 15 pM for tumor-derived GRF; effect within 30 seconds in perifusion; no demonstrable effect on other pituitary hormones [1] |
| Cultured rat anterior pituitary cells (second-messenger arm) | Intracellular cAMP after 1 nM hpGRF | About 6-fold increase within 5 min, maximal at 30 min; roughly 10 times more peptide needed for half-maximal cAMP than for half-maximal GH release [2] |
| HEK 293 cells expressing the cloned GHRH receptor | Binding and cAMP | Membrane binding of GHRH with high affinity and specificity; cAMP rise in transfected cells [3] |
| Cells co-expressing GHRH and secretagogue receptors | cAMP with GHRH alone or with a GH secretagogue | Co-activation produced a cAMP response about twice that of the GHRH receptor alone [4] |
| Primary porcine pituitary cells | GH and long-form leptin receptor mRNA at 4 h with [Ala15]-hGRF(1-29)NH2 | GH release up 120–151% over control at 10-8–10-6 M; Ob-Rl expression down 32–50% [5] |
The Ala15 peptide in the porcine study is a GRF(1-29) amide with a glycine-to-alanine change at position 15; it is a close analog of sermorelin, not the same molecule, and that distinction should be carried into any citation. The original rat studies used the native 44-residue human sequence, whose first 29 residues are the sermorelin sequence.
Where IGF-1 fits and where it does not
Search phrases that pair sermorelin with IGF-1 expect a single in vitro readout. In practice the two sit at different levels. GHRH acts on the somatotroph and the readout there is GH and its second messengers; IGF-1 is downstream of GH. Originally IGF-I was thought to be produced exclusively by liver under GH control, but later work showed that most tissues make it, and in a liver-specific igf-1 gene-deleted mouse postnatal growth and development were normal despite markedly reduced circulating IGF-I, with free IGF-I levels normal [6]. A pituitary monoculture therefore has no way to generate an IGF-1 response to a GHRH analog; a measured IGF-1 value requires a target tissue such as hepatocytes or fibroblasts exposed to conditioned medium, or an in vivo model. Designs that want to cover the axis in vitro are built as two stages: GHRH peptide on pituitary cells, then GH-containing conditioned medium on responsive cells, with each stage controlled separately.
Concentration arithmetic for cell work
Published work states concentrations in molar units; vials are labeled in milligrams. Conversion uses the molar mass from the formula (C149H246N44O42S, about 3,357.9 g/mol, calculated from the formula on the product page). No administration schedule is implied; these are unit conversions.
| Step | Formula | Worked example (unit conversion only) |
|---|---|---|
| Molar to mass concentration | mass conc. = molar conc. × 3,357.9 g/mol | 1 nM × 3,357.9 g/mol ≈ 3.4 ng/mL |
| Picomolar scale | same formula, 10-12 M | 15 pM ≈ 50 pg/mL |
| Serial dilution | Cfinal = Cstock × (Vtransferred ÷ Vtotal) | A 1:1,000 step lowers concentration a thousand-fold |
Take the vial label mass and the diluent volume only from your own protocol. Reaching picomolar working concentrations from a milligram-scale vial requires several serial dilution steps, because the stock is a million-fold or more above the assay. The reconstitution calculator does the stock division and peptide reconstitution volume calculations covers the series. Because the vial contains counterions and some water, the true molar value is lower than these figures; if the concentration matters, determine it by amino acid analysis or a validated absorbance measurement rather than from label mass.
Design points the literature highlights
- Negative and inhibitory controls. Somatostatin-28 and somatostatin-14 inhibited the GRF-induced GH release in a noncompetitive manner [1]. Including somatostatin as an inhibitor arm confirms that the signal is receptor-mediated physiology and not a nonspecific secretory artifact.
- Two readouts at different sensitivities. In one study somatostatin fully blocked GRF-stimulated GH release but only partially attenuated cAMP, and verapamil blocked release without lowering cAMP, which indicates that calcium is required for the release step after cAMP is generated [2]. A single readout can therefore hide the step at which a test condition acts.
- Counterion matching. In cultured osteoblasts, trifluoroacetate at 10-8–10-7 M reduced cell numbers and thymidine incorporation, and TFA salts of peptides gave less proliferation than hydrochloride salts [7]. If the lot is a TFA salt, a counterion control is warranted, particularly where the readout depends on proliferation or viability. Check the certificate for the salt form.
- Surface loss at low concentrations. Peptides at pM–nM concentrations adhere to plastic and glass; the choice of tubes and tips measurably changes recovery [8].
- Enzymatic loss in serum-containing medium. Plasma degrades native GHRH by N-terminal cleavage, with a 17-minute half-life of the intact 44-residue peptide by HPLC in one report [9]. Serum in culture medium is not plasma, and the rate in a given medium has not been published for sermorelin; if a long incubation is planned, measure stability in the medium used.
- Desensitization. In rat pituitary cells and animals, a GHRH analog given continuously at a high dose desensitized the GH response (29% of control) while continuous low-dose exposure sensitized it (129% of control) [10]. Time course and pulse design matter; one analog was studied, so the result describes a pattern, not a sermorelin-specific constant.
A minimal plate layout for a GH and cAMP experiment
The structure below follows the precedents above and keeps the experiment interpretable. It is a design template, not a validated protocol.
| Arm | Purpose | Readout |
|---|---|---|
| Vehicle only (same diluent and salt content) | Baseline and diluent control | GH in medium; cAMP in lysate |
| Peptide, 4–5 concentrations spanning pM to nM | Dose-response and the EC50 relation | GH at fixed time; cAMP at 5, 15 and 30 min |
| Peptide + somatostatin | Receptor-mediated inhibition | GH, cAMP |
| Peptide + phosphodiesterase inhibitor | Protects cAMP signal during accumulation | cAMP |
| Forskolin or 8-bromo-cAMP | Post-receptor positive control | GH, cAMP |
| Counterion control (TFA or acetate alone) | Separates peptide from salt effect | Viability and GH |
Identity and purity of the starting material underpin every row; how to read a COA and sermorelin purity testing describe what to verify before the first plate is seeded, and how to reconstitute a lyophilized peptide covers the bench steps. For the signaling logic behind the readouts, see the sermorelin research overview, and for the related secretagogue peptides compare ipamorelin and GHRP-2, which act through a different receptor. Browse the shop for related compounds.
All material discussed here is supplied for laboratory research use only; not for human consumption, and nothing in this article is a recommendation for any use outside a research setting.
Frequently asked questions
Can sermorelin be studied in a pituitary cell culture?
Yes. The classic model is primary rat anterior pituitary cells, where GHRH peptides release GH with a median effective concentration in the picomolar range and with a rapid onset.
Why can I not measure IGF-1 in a pituitary-only culture?
IGF-1 is produced mainly downstream of GH by the liver and other tissues, so a monoculture of somatotrophs has no IGF-1 source. A two-stage design with conditioned medium on responsive cells is needed.
What second messenger does the GHRH receptor use?
cAMP. GHRH raised cAMP about 6-fold within 5 minutes in cultured rat pituitary cells, and receptor-expressing HEK 293 cells also showed cAMP production.
Does somatostatin block the cAMP response completely?
Not in the study described: somatostatin fully blocked GH release but only partially attenuated cAMP, so it acts at least partly downstream of cAMP generation.
How do I convert nanomolar to micrograms per milliliter for sermorelin?
Multiply the molar concentration by about 3,357.9 g/mol, so 1 nM is about 3.4 ng/mL.
Is the TFA salt a concern for cell assays?
It can be. TFA at nanomolar to tens of nanomolar concentrations reduced proliferation in osteoblast cultures, so a counterion control is sensible for proliferation-sensitive readouts.
Do results from the porcine Ala15 peptide apply to sermorelin?
They are informative, but the Ala15 analog has a Gly15-to-Ala change, so the results are for a related molecule and should be cited as such.
Is there a published stability figure for sermorelin in culture medium?
Not that this article could verify. The published plasma data concern the native 44-residue hormone, so stability in the medium used should be measured.
Related reading: Sermorelin Mechanism: GHRH Receptor and cAMP Signaling, Sermorelin Half-Life: What Published Studies Measured, Sermorelin Preclinical Research: Animal Model Map.
References
- Brazeau P, Ling N, Böhlen P, Esch F, Ying SY, Guillemin R. Growth hormone releasing factor, somatocrinin, releases pituitary growth hormone in vitro. Proc Natl Acad Sci U S A. 1982;79(24):7909-13. doi:10.1073/pnas.79.24.7909
- Bilezikjian LM, Vale WW. Stimulation of adenosine 3',5'-monophosphate production by growth hormone-releasing factor and its inhibition by somatostatin in anterior pituitary cells in vitro. Endocrinology. 1983;113(5):1726-31. doi:10.1210/endo-113-5-1726
- Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol. 1992;6(10):1734-44. doi:10.1210/mend.6.10.1333056
- Cunha SR, Mayo KE. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology. 2002;143(12):4570-82. doi:10.1210/en.2002-220670
- Lin J, Barb CR, Kraeling RR, Rampacek GB. Growth hormone releasing factor decreases long form leptin receptor expression in porcine anterior pituitary cells. Domest Anim Endocrinol. 2003;24(2):95-101. doi:10.1016/s0739-7240(02)00209-6
- Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev. 2001;22(1):53-74. doi:10.1210/edrv.22.1.0419
- Cornish J, Callon KE, Lin CQ, Xiao CL, Mulvey TB, Cooper GJ, et al. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am J Physiol. 1999;277(5):E779-83. doi:10.1152/ajpendo.1999.277.5.E779
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
- Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest. 1986;78(4):906-13. doi:10.1172/JCI112679
- Kovács M, Fáncsik A, Mezö I, Teplán I, Flerkó B. Effects of continuous and repetitive administration of a potent analog of GH-RH(1-30)NH2 on the GH release in rats. Neuroendocrinology. 1994;59(4):371-9. doi:10.1159/000126680
